This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy PTC Therapeutics stock | $61.2

Own PTC Therapeutics stock in just a few minutes.

Posted

Fact checked

PTC Therapeutics, Inc is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. PTC Therapeutics employs 754 staff and has a trailing 12-month revenue of around USD$358.4 million.

How to buy shares in PTC Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for PTC Therapeutics. Find the stock by name or ticker symbol: PTCT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until PTC Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$61.2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of PTC Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of PTC Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

PTC Therapeutics share price

Use our graph to track the performance of PTCT stocks over time.

PTC Therapeutics shares at a glance

Information last updated 2020-12-03.
Latest market close USD$61.2
52-week range USD$30.7923 - USD$64.62
50-day moving average USD$57.738
200-day moving average USD$51.8221
Wall St. target price USD$61.58
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.1

Buy PTC Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PTC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PTC Therapeutics price performance over time

Historical closes compared with the close of $61.2 from 2020-11-16

1 week (2020-11-25) N/A
1 month (2020-11-06) 3.07%
3 months (2020-09-02) N/A
6 months (2020-06-02) N/A
1 year (2019-12-02) N/A
2 years (2018-12-02) N/A
3 years (2017-12-02) N/A
5 years (2015-12-02) N/A

Is PTC Therapeutics under- or over-valued?

Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PTC Therapeutics's PEG ratio

PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

PTC Therapeutics financials

Revenue TTM USD$358.4 million
Gross profit TTM USD$37.4 million
Return on assets TTM -10.26%
Return on equity TTM -75.17%
Profit margin -123.2%
Book value $7.535
Market capitalisation USD$4.4 billion

TTM: trailing 12 months

Shorting PTC Therapeutics shares

There are currently 4.7 million PTC Therapeutics shares held short by investors – that's known as PTC Therapeutics's "short interest". This figure is 3.8% up from 4.5 million last month.

There are a few different ways that this level of interest in shorting PTC Therapeutics shares can be evaluated.

PTC Therapeutics's "short interest ratio" (SIR)

PTC Therapeutics's "short interest ratio" (SIR) is the quantity of PTC Therapeutics shares currently shorted divided by the average quantity of PTC Therapeutics shares traded daily (recently around 436328.86405959). PTC Therapeutics's SIR currently stands at 10.74. In other words for every 100,000 PTC Therapeutics shares traded daily on the market, roughly 10740 shares are currently held short.

However PTC Therapeutics's short interest can also be evaluated against the total number of PTC Therapeutics shares, or, against the total number of tradable PTC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PTC Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 PTC Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0704% of the tradable shares (for every 100,000 tradable PTC Therapeutics shares, roughly 70 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PTC Therapeutics.

Find out more about how you can short PTC Therapeutics stock.

PTC Therapeutics share dividends

We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.

PTC Therapeutics share price volatility

Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $30.7923 up to $64.62. A popular way to gauge a stock's volatility is its "beta".

PTCT.US volatility(beta: 1.18)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 1.1838. This would suggest that PTC Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

PTC Therapeutics overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site